ClinicalTrials.gg
WithdrawnNCT03418272Updated Apr 22, 2022

Cultures in PICU Patients Compared to Healthy Children

An observational study in Ventilator Associated Pneumonia and Pneumonia, Bacterial, sponsored by State University of New York at Buffalo. Withdrawn. Open to participants aged 2 Years to 8 Years. Per ClinicalTrials.gov, last updated 2022-04-22.

Sponsored by State University of New York at Buffalo · Observational

Why this study was withdrawn
Study withdrawn until time and staff allow its completion.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
0
Ages
2 Years to 8 Years
Sex
All
01

Study summary

This study is being done to determine if the bacteria found in your mouth (oral flora bacteria) in children admitted to the intensive care unit who need to be on a breathing machine is different from the oral flora in healthy children undergoing anesthesia for their dental caries. Children in the intensive care unit with a breathing tube are at a higher risk for getting a lung infection due to the bacteria in the mouth slipping into their lungs past the breathing tube over several days. This means that bacteria are found in the child's lung when this is normally not the case. If the bacteria in the mouth have changed from normal then they may get a pneumonia.

Read the detailed description

The oral cavity has natural flora of microbiology that may be associated with the development of dental decay. Another possible problem arising from this flora is the migration of the bacteria into the trachea causing pulmonary infections such as trachietis or pneumonia. The risk of developing a pulmonary infection appears to be increased in patients who have been intubated for a period of time (days) such as those patients ventilated in the intensive care unit (ICU). It has also been shown that in patients in the ICU the nature of the oral flora changes over time to include bacteria that are more commonly associated with the nosocomial pneumonia, ventilator associated pneumonia. We have previous demonstrated in a small pilot study (CYIRB2779) that the changes in the oral flora in children intubated in the ICU was similar to those bacteria grown from tracheal cultures ordered by the intensivist. Patients intubated in the ICU maybe at risk of decreased salivary flow, sedated and unable to clear secretions and are reliant on the bedside nurse to maintain adequate oral hygiene. Most ICU's have guidelines and policies to ensure that oral hygiene is appropriately cared for. They are also at risk for changes in the oral flora due to concomitant broad-spectrum antibiotic use that is common in the initial 48 hours after admission with respiratory failure.

The second are of interest is to determine whether children who are very sick and require intubation and ventilation support have different bugs growing in their mouth that may predispose them to future infection whilst in the ICU.

02

Conditions studied

  • Ventilator Associated Pneumonia
  • Pneumonia, Bacterial

Keywords

  • ICU
  • OR
  • Pneumonia
  • PICU
  • Pediatric
  • PCR
03

In context

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Lead sponsor

State University of New York at Buffalo is the lead sponsor of 294 studies on the registry; 63 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 8 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

ICU Group:

  • Intubated within 12 hours
  • ASA 1 or 2 (ASA - AMERICAN SOCIETY ANESTEHESIOLOGY PREOPOERATIVE STATUS)
  • Age 2 to 8

OR Group:

  • ASA 1 or 2
  • Elective dental surgery requiring intubation
  • Age 2 to 8

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

ICU Group:

  • Intubated within 12 hours
  • ASA 1 or 2 (ASA - AMERICAN SOCIETY ANESTEHESIOLOGY PREOPOERATIVE STATUS)
  • Age 2 to 8

OR Group:

  • ASA 1 or 2
  • Elective dental surgery requiring intubation
  • Age 2 to 8

Exclusion criteria

Exclusion Criteria:

ICU Group:

  • Trauma patients
  • Postoperative patients
  • Children under 2 or over 8

OR Group:

  • Received antibiotics within the last week
  • Received prednisone within the last 2 weeks
  • Viral respiratory infective process within the last 2 weeks
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Ventilated Pediatric Intensive Care Unit patient Group

    This will be a prospective descriptive case series where tracheal cultures and PCR results will be analyzed at initial intubation and again several days into the ICU stay.

    Diagnostic Test: Culture/PCR Analysis

  • Intubated OR patient Control Group

    For the healthy operating room children, also a case series where a single set of studies will be obtained. tracheal cultures and PCR results will be analyzed after intubation These two groups will be compared, non-randomized.

    Diagnostic Test: Culture/PCR Analysis

Interventions

  • Diagnostic testCulture/PCR Analysis

    Microbes to be selectively cultured and PCR analysis to be conducted. Bacteria obtained in samples will be dispersed in non-selective Mueller Hinton Broth (Sigma-Aldrich), divided into two separate cultures and grown overnight at 37°C in aerobic condition and in 5% CO2 to assure survival of both aerobic and facultative anaerobic species. * Staphylococcus aureus (MSSA, MRSA) * Pseudomonas aeruginosa * Haemophilus influenza * Streptococcus pneumonia * Streptococcus Pyogenes Group B streptococci, * Klebsiella pneumonia * Moraxella catarrhalis

06

What researchers measure

Primary outcomes

  1. Percentage of bacteria in sample

    PCR analysis

    Time frame: By January 2019

  2. Presence of bacteria in sample

    Culture analysis

    Time frame: By January 2019

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2023; primary completion for May 2023, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2018
First posted
Feb 1, 2018
StartEst.
Feb 2023
Primary completionEst.
May 2023
CompletionEst.
Sep 2023
Last update
Apr 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03418272
Responsible party
Christopher Heard (Clinical Professor of Anesthesiology, State University of New York at Buffalo) — Principal investigator
First posted
Feb 1, 2018
Start date
Feb 2023 (estimated)
Primary completion
May 2023 (estimated)
Completion
Sep 2023 (estimated)
Last update
Apr 22, 2022

Study contacts

Christopher Heard, MBChB, FRCA
principal investigator · Jacobs School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion